I think you've hit it exactly. There's no reason to think that resolving IP concerns will speed up production and deployment in India. Problems there have more to do with the state of their logistical and healthcare infrastructure than the (very impressive) vaccine production capabilities of the Serum Institute of India.

It's also maybe a little relevant that the Modi government didn't order nearly enough vaccines early enough.